WO2007043486A1 - 生体適合性ブロック共重合体、その用途および製造法 - Google Patents
生体適合性ブロック共重合体、その用途および製造法 Download PDFInfo
- Publication number
- WO2007043486A1 WO2007043486A1 PCT/JP2006/320140 JP2006320140W WO2007043486A1 WO 2007043486 A1 WO2007043486 A1 WO 2007043486A1 JP 2006320140 W JP2006320140 W JP 2006320140W WO 2007043486 A1 WO2007043486 A1 WO 2007043486A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- block copolymer
- drug
- acid
- leu
- drugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
Definitions
- the present invention relates to a biocompatible block copolymer having a hydrophobic segment consisting of an amino acid and a hydroxycarboxylic acid and a hydrophilic segment consisting of a polyalkylene oxide, a micelle comprising the biocompatible block copolymer and a drug, and fine particles
- the present invention also relates to composites and their uses, pharmaceutical compositions containing them, and methods for producing the same. These micelles, microparticles, or complexes enable drug solubilization, dispersion, stabilization, sustained release, and delivery to lesion sites. 'Background technology
- the drug exhibits its effect by reaching the drug action site in the living body.
- a drug cannot reach its site of action.
- the drug (1) is difficult to dissolve in body fluids, (2) is unstable under enzyme, pH, or other physiological conditions, (3) cannot pass through membrane barriers such as endothelium and mucous membrane (4) causing an undesirable immune response, (5) rapidly disappearing and excreting from the blood, (6) lack of targeting ability to the target site, etc. .
- biodegradable polymer for drug delivery examples include polyoxyacid obtained by ester condensation of hydroxycarboxylic acid having a hydroxyl group and a carboxyl group in the molecule.
- ester bond since the ester bond does not have a hydrogen atom, it has been clarified that no hydrogen bond is generated in the ester bond and it is more easily biodegradable than a polyamino acid.
- a non-catalyzed method for polymerizing hydroxycarboxylic acid from hydroxycarboxylic acid and water has been developed.
- Polymers obtained by polycondensation of oligomers that do not contain catalyst residues use metal catalysts when used in drug delivery systems.
- Polyoxyacids have a faster biodegradation rate for lower molecular weight samples, and in particular, low molecular weight poly-DL-lactic acid is the preferred drug delivery system (M Asano, H Fukuzaki, M. Yoshida, M. Kumakura, T Mashimo, H Yuasa, K Imai, H Yamanaka, K Suzuki, J Control led Release, (1989) 9 111, M Asano, H Fukuzaki, M Yoshida, M. Kumakura, T Mashimo, H.
- polymeric micelles are basically nanoparticles formed with a hydrophilic segment as the outer shell and a hydrophobic segment as the inner core. Solubilization, stabilization, and sustained release of drugs. Many reports have been made on delivery carriers.
- a drug-supporting carrier for a block copolymer comprising a hydrophilic segment such as polyalkyleneoxide and a hydrophobic segment such as polyalkyl spartate (Japanese Patent Laid-Open No. 06-107565, Japanese Patent Laid-Open No.
- JP-A 06-206830 JP-A 06-206832, JP-A 11-100331, JP-A 2001-226294, JP-A 2003-342167, JP-A 2004-010479, JP-A 2004-35 2972 JP 2005-029480, JP 2005-501831 and WO 03Z000771 pamphlet), a block copolymer comprising a hydrophilic segment such as a hydrophilic polyamino acid and a hydrophobic segment such as polylactide. Fine particles (see JP-A-11-269097), hydrophilic segments such as polyethylene glycol, and blocks containing charged segments such as polyamine polypolyuronic acid.
- biodegradable plastics consisting of amino acids and hydroxycarboxylic acids
- depsipeptide copolymers obtained by polymerizing optically active 3-substituted 1,2,5-morpholinediones and cyclic lactones, and bioabsorption produced from polydepsipeptides.
- Surgical devices, etc. see JP-A-7-188411
- biodegradable polylactone ester amides having specific polyamide units, specific polyester units, and specific polylactone units (See 11-35679)
- a polymer composed of a specific depsipeptide and polylactic acid has good biodegradability, and can improve flexibility while maintaining strength (see JP 2001-31762).
- the moldability is good and it has the functionality corresponding to various utilization forms (see JP 2002-234934 A).
- one of the inventors of the present invention discloses a method for synthesizing a depsipeptide and a synthetic product (see JP-A-2004-269462).
- any of the above-mentioned Japanese Patent Laid-Open Nos. 7-188411, 11-35679, 2001-31762, 2002-234934, and 2 004-269462 Similarly, a biocompatible block copolymer having a hydrophobic segment consisting of an amino acid and hydroxycarboxylic acid and a hydrophilic segment consisting of a polyalkylene oxide, and a micelle, microparticle, There is no description regarding complex formation.
- a ternary block copolymer has been reported as a biodegradable plastic comprising a block comprising an amino acid and a hydroxycarboxylic acid and a block comprising a polyalkylene glycol (see International Publication No. 2005/003214 Panflate). .
- An object of the present invention is to provide a biocompatible block copolymer having affinity for a drug, which makes it possible to eliminate the above six causes that the drug cannot reach its site of action.
- Another object of the present invention is to have an ester bond that is easily cleaved in vivo and an amide bond that is difficult to cleave, exhibit no antigenicity, and control the type, number, and sequence of amino acids and hydroxycarboxylic acids. It is an object of the present invention to provide a biocompatible block copolymer that can control the affinity with a drug.
- Still another object of the present invention is to comprise the above-mentioned biocompatible block copolymer and a drug, and solubilize, disperse, stabilize, and release the drug and deliver the drug to a necessary site in the living body. It is to provide micelles, microparticles, or composites that make it possible.
- Still another object of the present invention is to provide an advantageous process for producing the micelles, fine particles and composites.
- the above objects and advantages of the present invention include, firstly, a hydrophobic segment consisting of an amino acid and hydroxycarboxylic acid and a hydrophilic segment consisting of polyalkyleneoxide and the hydrophilicity of the hydrophobic segment. This is achieved by a biocompatible block copolymer characterized in that the end not bound to the segment consists of amino acid units.
- a micelle comprising the biocompatible block copolymer of the present invention and a drug.
- microparticles or composites comprising the biocompatible block copolymer of the present invention and a drug.
- the above objects and advantages of the present invention are fourthly achieved by a pharmaceutical composition containing the micelle, microparticle or complex of the present invention.
- a biocompatible block copolymer having a hydrophobic segment composed of an amino acid and a hydroxycarboxylic acid, and a hydrophilic segment composed of a polyalkylene oxide is achieved by a method for producing a micelle or a complex containing a drug characterized by mixing the compound and the drug in water.
- the above objects and advantages of the present invention include, finally, a biocompatible block copolymer having a hydrophobic segment consisting of an amino acid and hydroxycarboxylic acid and a hydrophilic segment consisting of a polyalkylene oxide, It is achieved by a method for producing micelles, microparticles or composites characterized in that a mixed solution comprising a drug and a solvent is prepared and the solvent is removed from the mixed solution.
- a biocompatible block copolymer having a hydrophobic segment consisting of an amino acid and hydroxycarboxylic acid and a hydrophilic segment consisting of a polyalkylene oxide
- biocompatible block copolymer of the present invention has a hydrophobic segment and a hydrophilic segment.
- biocompatibility ⁇ means a property that is compatible with a living tissue and shows no damage to the living body after administration in vivo, for example, it is decomposed and metabolized in vivo or not decomposed.
- biodegradable refers to a property that, after being administered into a living body, is decomposed and metabolized in a living tissue and does not show any damage to the living body. Okay, for example, the property of being decomposed and metabolized in the body and finally excreted outside the body.
- the “hydrophobic segment” is a biodegradable polymer or a derivative thereof which is hardly soluble or insoluble in water, and is more hydrophilic than the hydrophilic segment which is the other component forming the block copolymer. Also refers to a high molecular polymer that is hydrophobic.
- the term “hydrophilic segment” refers to a high molecular weight polymer that is soluble in water or is hydrophilic to the hydrophobic segment of the block copolymer even though it is sparingly soluble in water. It refers to its derivative.
- “micelle” means a particle having an inner core portion and an outer shell portion having different compositions.
- the term “fine particles” means an average particle size of 300 ⁇ m or less, no clear inner core and outer shell portion, and almost uniform dispersion of the drug in the block copolymer.
- the term “complex” refers to a complex that does not have a clear inner core and outer shell and is formed by the interaction between a drug molecule or drug crystal and the present block copolymer.
- ligand generally refers to any molecule that can specifically bind to a specific target molecule and form a binding complex, and is the leading moiety toward the target.
- the biocompatible block copolymer of the present invention comprises an amino acid as a hydrophobic segment.
- a biocompatible block composed of a biodegradable block composed of a hydroxycarboxylic acid and a polyalkylene oxide serving as a hydrophilic segment is a block copolymer in which a hydrophilic segment is covalently bonded to the end of a biodegradable hydrophobic segment. These segments may be bonded directly or via a spacer having a linking group.
- a block copolymer for example, the following formula (1)
- R 2 is a side chain of a natural amino acid or a derivative thereof;
- R 3 is a hydrogen atom, an alkyl group or
- R 4 is a hydrogen atom or a methyl group;
- m is an integer from 1 to 20;
- p is an integer from 1 to 20 and Q is from 0 to 20
- r is an integer of 2 to 870).
- the hydrophobic segment of the block copolymer used in the present invention is a compound comprising an amino acid and a hydroxycarboxylic acid, as shown in the above formula (1).
- the amino acid used is not particularly limited as long as it is biodegradable or biocompatible.
- DL-amino acids, D_a-amino acids, synthetic amino acids, and derivatives in the side chains of these amino acids can also be used.
- amino acids include glycine, alanine, norine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, proline, hydroxyproline, cysteine, methionine, dalbutamate, aspartate, lysine, Arginine, histidine, hydroxylysine,
- Examples include 4-hydroxyproline, homoproline, norvaline> norleucine, ⁇ -t-butydaricin, cyclohexylglycine, asparagine, glutamine, and j8-cyclohexylalanine.
- glycine, alanine, norin, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, glutamic acid, aspartic acid, lysine and arginine are preferably used.
- alanine, valine, leucine, isoleucine, phenylalanine, glutamic acid, aspartic acid, lysine and arginine are particularly preferably used.
- the hydroxycarboxylic acid used is not particularly limited as long as it is biodegradable or biocompatible, but not only hyhydroxycarboxylic acid but also other hydroxycarboxylic acids can be used. Specific examples include glycolic acid, lactic acid, hydroxybutyric acid, hydroxyvaleric acid, hydroxycabronic acid and hydroxycapric acid. Of these, glycolic acid and lactic acid are particularly preferably used.
- the hydrophobic segment of the block copolymer used in the depsipeptide and the present invention may be a depsipeptide compound composed of an ⁇ -amino acid and an ⁇ -hydroxycarboxylic acid.
- the ⁇ -amino acid used is not particularly limited as long as it is biodegradable or biocompatible, but not only natural L-amino acid, but also DL- ⁇ -amino acid, D— ⁇ -amino acid, synthesis One amino acid can be used.
- Specific examples of ⁇ -amino acids include amino acids among the amino acids described above and derivatives in the side chains thereof.
- the ⁇ -hydroxycarboxylic acid used is not particularly limited as long as it is biodegradable or biocompatible, but glycolic acid and lactic acid, which are ⁇ -hydroxycarbonic acids among the hydroxycarboxylic acids described above, are used. It is particularly preferably used.
- Depsipeptides have an amide bond and an ester bond in the molecule, and the amide bond part has a hydrogen atom, so an intermolecular hydrogen bond is formed to form a strong intermolecular bond, but the ester bond part has a hydrogen atom. Since it does not have, intermolecular hydrogen bond is formed It is relatively easy to be hydrolyzed. Therefore, depsipeptides with an ester bond in the amide bond chain are prone to degradation in vivo, and the degradation rate can be controlled by the type and number of amino acids, the type and number of hydroxycarboxylic acids, and their sequence. .
- Polyamino acids often have a problem with their antigenicity, but they are said to exhibit little antigenicity in peptides with about 5 amino acids or less. It is possible to design the molecule so as not to show antigenicity in debupeptide.
- Polydepeptidic peptides exhibit completely different physicochemical properties depending on the type of amino acid constituting the polydepeptidic acid, the length of the sequence, and the type of hydroxycarboxylic acid.
- the teradepsipeptide sequence with three amino acids linked and one hydroxycarboxylic acid is completely different from the tridepsipeptide sequence with two amino acids and one hydroxycarboxylic acid. Stability and micelle formation ability.
- polydebupeptides having various properties can be synthesized by changing the type of amino acid and the type of hydroxycarboxylic acid.
- polydepeptidides having 3 to 5 amino acid sequences and 1 to 3 hydroxycarboxylic acids bonded thereto are preferred.
- the number n of amino acids constituting the polyamino acid of the hydrophobic segment of the block copolymer represented by formula (1) is an integer of 1 to 20, preferably an integer of 1 to 10, more preferably It is an integer from 1 to 6.
- the number q of amino acids constituting the polyamino acid on the hydrophilic segment binding side of the hydrophobic segment is an integer of 0 to 20, preferably an integer of 0 to 10, and more preferably an integer of 0 to 6.
- the number m of oxy acids constituting the polyhydroxycarboxylic acid of the hydrophobic segment is an integer of 1 to 20, preferably an integer of 1 to 10, more preferably an integer of 1 to 5.
- the repeating number p of the amino acid hydroxycarboxylic acid conjugate is an integer of 1 to 20, preferably an integer of 1 to 10, more preferably an integer of 1 to 5.
- the number k of methylene group and substituted methylene group of hydroxycarboxylic acid is an integer of 1-6.
- n, p or q is an integer of 2 to 20 a plurality of R 2 may be the same or different, and when m or p is an integer of 2 to 20 a plurality of R 3 are the same But different Furthermore, a plurality of R 4 s when r is 2 or more may be the same or different.
- the end of the hydrophobic segment of the block copolymer represented by the formula (1) is a hydrogen atom, an alkyl group, a substituted alkyzole group or an amino group protecting group.
- the amino-protecting group include t-butoxycarbonyl group (B o c—), benzyloxycarbonyl group (Z—), 9-fluorenylmethyloxycarbonyl group (Fm o c 1) and the like.
- t_butoxycarbonyl group (B o c-) is preferably used.
- R 2 represents a side chain of a natural amino acid or a derivatized side chain (hereinafter referred to as a derivative group), and each amino acid unit independently represents a side chain of a natural amino acid or one of its derivative groups.
- the amino acid derivative having a derivative group include power of glutamic acid 5-derivative, aspartic acid 4 derivative, lysine ⁇ _derivative and the like.
- Glutamic acid 5-derivative, aspartic acid 4 Derivatives include derivatives in which the carboxyl group at the end of the side chain is protected with a protecting group, alkyl ester compounds such as methyl ester and ethyl ester, ester compounds with drug hydroxyl groups, and drug amino groups.
- lysine derivatives include derivatives in which the terminal amino group of the side chain of lysine is protected with a protecting group, amides with the carboxyl group of the drug, and conjugates with the drug via spacers. I can get lost.
- glutamic acid 5-ethyl ester units, aspartic acid 4-ethyl ester units, and lysine units whose terminal amino groups are protected with benzyloxycarbonyl groups are preferably used.
- R 3 represents a side chain of hydroxycarboxylic acid, and each hydroxycarboxylic acid independently represents a hydrogen atom, an alkyl group or a substituted alkyl group.
- alkyl groups having 1 to 3 carbon atoms or those substituted with substituents are preferred. Examples of such an alkyl group include a methyl group, an ethyl group, a propyl group, and an isopropyl group. Examples of the substituent include a methyl group, an ethyl group, and a propyl group. Can be mentioned.
- the hydrophilic segment of the block copolymer used in the present invention is made of polyalkylene oxide, and more specifically, mention may be made of polyethylene glycol, polyethylene diol Z polypropylene glycol block copolymer, and polypropylene glycol. Can do. More preferred is polyethylene glycol.
- the repeating number r of alkylene oxide is 2 to 870, preferably 3 to 570, more preferably 3 to 250.
- R 4 is a hydrogen atom or a methyl group.
- R 5 in the above formula (1) represents a hydrogen atom, an alkyl group, a substituted alkyl group, a ligand residue, a ligand residue having a linking group, or a formula Ri — [[one NHCH (R 2 ) CO-] n _ ⁇ — O [CH (R 3 )] k CO- ⁇ m- ) p- [One NHCH (R 2 ) CO—]. (Wherein R 2 , R 3 , n, k, m, p and Q have the same definitions as _h).
- ligands include lectins, antibodies, antibody fragments (eg, Fab' fragments), lymphokines, site force-in, receptor proteins (eg, CD 4, CD 8, CD 44, CD 71, etc.), Nucleic acids, antigens, hormones, adhesion factors (eg VCAM-1, ICAM-1, PECAM-1, RGD, NGR, etc.), transferrin, folic acid, growth factors (eg EGF, bFGF, VEGF, etc.) and desired And the like that specifically bind to the target cells.
- the block copolymer of the present invention can be produced, for example, as follows.
- the amino acid N-hydroxysuccinimide ester having a protected amino group is reacted with the amino group of the terminal amino acid to obtain a protected dipeptide-linked polyalkylene oxide.
- the amino group produced by removing the protecting group is reacted with an oligodepsipeptide N-hydroxysuccinimide ester whose terminal amino group is protected and the other terminal is composed of hydroxycarboxylic acid.
- Halogen and halogenated thionyl are allowed to act on the hydroxycarboxylic acid to obtain a hydroxycarboxylic acid halide, which is reacted in the presence of an amino acid or an alkali polyamino acid to obtain a depsipeptide.
- an amino acid has other functional groups in addition to the two functional groups, an amino group and a force lupoxyl group, it is preferable that the other functional group is bonded to a protecting group during the production of the polydepsipeptide.
- this amino acid derivative can be closed by heating in the presence of an alkali to obtain a cyclic depsipeptide.
- a catalyst such as stannous octylate, a cyclic depsipeptide and a polyalkylene oxide, a mono-substituted polyalkylene oxide, or a polyalkylene oxide in which one hydroxyl group is protected are reacted to form an amino acid.
- a catalyst such as stannous octylate, a cyclic depsipeptide and a polyalkylene oxide, a mono-substituted polyalkylene oxide, or a polyalkylene oxide in which one hydroxyl group is protected are reacted to form an amino acid.
- a block copolymer having a hydrophobic segment composed of hydroxycarboxylic acid and a hydrophilic segment composed of polyalkylene oxide can be obtained.
- a hydrophobic segment comprising an amino acid and a hydroxycarboxylic acid can be synthesized by the method described in Japanese Patent Application Laid-Open No. 2000-046 9 4 62 filed by one of the present inventors. . That is, the carboxyl group of an amino acid having a protected amino group and the hydroxy group of a hydroxycarboxylic acid having an unprotected carboxyl group. Didepsipeptides are synthesized by reacting droxyl groups with aminopyridine compounds as catalysts.
- the carboxyl group of the obtained dedepeptide is used as an imide derivative, and the protected amino group of the didepsipeptide is deprotected, and the deprotected amino group of the resulting didepsipeptide and the protected amino group
- An oligodepsipeptide is synthesized by reacting with a carboxyl group of an amino acid having an amino acid.
- the reaction in which the protected amino acid or the protected oligodepeptide is bound to the polyalkylene oxide can be carried out in an appropriate solvent for dissolving them, such as chloroform, dichloromethane, tetrahydrofuran, acetonitrile, or ethyl acetate.
- an appropriate solvent for dissolving them such as chloroform, dichloromethane, tetrahydrofuran, acetonitrile, or ethyl acetate.
- the product is dissolved in dichloromethane or chloroform, and this is washed with an aqueous solution of sodium hydrogen carbonate, an aqueous solution of citrate, etc. to remove by-products, and after distilling off the solvent, ether is removed.
- pure product is precipitated and isolated.
- the block copolymer of the present invention can be used not only to form micelles with drugs, fine particles containing drugs, and complexes with drugs, but also to produce vesicles such as ribosomes. it can. Depending on the purpose, the micelles, microparticles or complexes can be incorporated into liposomes.
- the block copolymer of the present invention can be used together with a drug.
- a drug any of biologically active compounds such as natural products, synthetic products, semi-synthetic products, fermentation products, biological materials, and genetic engineering products can be used. Synthetic bioactive compounds, peptides, proteins, hormones, vitamins, enzymes, coenzymes, fatty acids, lipids, genes, this Any of these derivatives may be used.
- the drug may be water-insoluble, poorly water-soluble, fat-soluble, or water-soluble.
- examples of such drugs include anti-inflammatory drugs (for example, non-steroidal drugs such as mefenamic acid, bufuexamac, and ferbinac, steroidal drugs such as dexamethasone, prednisolone, and beclomethasone), and antipyretic drugs (for example, , Acetaminophen, alclofenac, bufuexamac, etc.), analgesics (eg, aminovirin, acetominophen, morphine, buprenorphy), anti-arthritis drugs * anti-rheumatic drugs (eg, auranofin, azathioprine, methotrexa) ), Anti-gout drugs (eg, aloprino, probenecid, sulfinpyrazone), cardiotonics (eg, oxipheedrin, theopromine), anti-anginal agents (eg, alpren
- the drug may be either hydrophilic or hydrophobic.
- the block copolymer of the present invention can form micelles. Micelles have a hydrophobic segment in the inner core of the micelle and a hydrophilic segment in the outer shell of the micelle. May be present in the inner core of micelles, hydrophobic segments may be present in the outer shell of micelles, and both segments may be present randomly in the vehicle and may not have a domain structure. When the inner micelle core consists of hydrophobic segments, it is preferable to select a hydrophobic drug, and when the inner micelle core consists of hydrophilic segments, it is preferable to select a hydrophilic drug. For the drug, either a hydrophilic or hydrophobic drug can be selected.
- hydrophobic drugs examples include non-steroidal anti-inflammatory drugs (eg, indomethacin, naproxen), steroidal anti-inflammatory drugs (eg, dexamethasone, dexamethasone valerate, dexamethasone palmitate, triamcinolone, triamcinolone acetonide , Parazozone acetate, haloprezone acetate, hydrocortisone, flucortisone acetate, prednisolone butyl acetate, prednisolone acetate valerate, prednisolone acetate, betamethasone methazone valerate, antitumor drugs (for example, paclitaxel, Camptothecin, epotosid, vinblastine, fluouracil, methotrexate, tegafur, tegafur uracil, toggleomycin / C, sizplatin, force lupocon, dacarbazine, mercaptop Phosphorus
- a water-soluble polypeptide As a hydrophilic drug, for example, a water-soluble polypeptide is used.
- water-soluble polypeptides include cyto force-in, hematopoietic factors, various growth factors, and enzymes.
- site power-in is preferable, for example, lymphokine (for example, Yinyu Ferron and Interferon) 8, Interferon, Interleukin (IL 1-2 to IL-12), mono force-in (Inter 1). Leukin 1 and tumor necrosis factor (TNF)).
- drugs include luteinizing hormone-releasing hormone and derivatives or analogs, insulin and derivatives or analogs, somatosutin and derivatives or analogs, growth hormone, growth hormone-releasing hormone, prolactin, Ellis mouth boyetin, adrenal gland Cortical hormones and derivatives or analogs, melanocyte stimulating hormone, thyroid hormone releasing hormone and derivatives or analogs, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, vasopressin and derivatives, oxytocin, calcitonin and derivatives or analogs, Glucagon, gastrin, secretin, pancreosymine, cholecystokinin, angiotensin, human placental ketogen, human chorionic gonadotropin, enkephalin and derivatives Or analogs, endorphins, chitotorphins, tuftsin, thymopoietin, thymosin, thymothymline, thymic factor, blood th
- the drug used in the present invention may be in a pharmacologically acceptable form as well as itself.
- a basic group such as an amino group, an inorganic acid (for example, hydrochloric acid, sulfuric acid, nitric acid, boric acid, etc.) or an organic acid (for example, carbonic acid, bicarbonate, succinic acid, Salts with acetic acid, propionic acid, fumaric acid, trifluoroacetic acid, etc.).
- the drug is a carboxyl group or the like
- an inorganic base for example, an alkali metal such as sodium or potassium or an alkaline earth metal such as calcium or magnesum
- an organic base for example, an organic amine such as trytylamine, arginine
- the drug may form a metal complex compound such as a copper complex or a zinc complex.
- a drug-containing micelle containing the block copolymer of the present invention as a constituent, for example, a thin-film water stirring method, a solution-water dilution method, a dialysis method, or the like is used, and these are used alone or in combination.
- block copolymers of the present invention at least one type of block copolymer having micelle-forming ability and a drug are dissolved in a solvent, and then placed in a container, and the solvent is removed to form a thin film. Water is added to this and stirred to form micelles.
- the solvent used here is not particularly limited as long as it can dissolve the block copolymer and the drug.
- tetrahydrofuran, dioxane, acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide, Methanol, ethanol, benzene, toluene, dimethylacetamide, dimethylformamide, etc. are used. Either can be used alone or in combination.
- additives can be added to the aqueous phase.
- additives include pH adjusting agents (for example, phosphate buffer, carbonate buffer, acetate buffer, dilute hydrochloric acid, sodium hydroxide, etc.), anionic surfactants, nonionic surfactants, polyoxy Emulsifiers such as ethylene castor oil derivatives, polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxymethyl cellulose, lecithin, gelatin, hyaluronic acid, and sugars such as mannitol are used.
- the preparation temperature is preferably about 0 to about 8, more preferably about 5 to about 50 ° C.
- the residual solvent can be removed by applying an external shearing force or ultrasonic irradiation during stirring in water, or by evaporating the evaporator in accordance with a conventional method under reduced pressure conditions.
- the device for applying the external shearing force include a turbine type agitator and a homogenizer.
- At least one type of block copolymer having the ability to form micelles and a drug in the block copolymer of the present invention and a drug are dissolved in a solvent, and then added to water little by little with stirring, and the solvent is removed in water to form a polymer.
- the solvent used here is not particularly limited as long as it is miscible with water. For example, 'methanol, ethanol, dimethylacetamide, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxane, acetone, and acetonitrile. Or a mixture of these and water is used. Solvents can be used alone or in combination of two or more.
- a combination of tetrahydrofuran, acetone and water is preferably used. Since the good solvent for the block copolymer naturally varies depending on the composition of the polymer, it is preferable to select a solvent according to the polymer used.
- the additives in the aqueous phase described in the section of the thin film underwater stirring method may be similarly added.
- the preparation temperature is preferably about 0 ° C to about 80 ° C, more preferably about 5 ° C to about 50 ° C.
- the solvent can be removed by applying an external shearing force or ultrasonic irradiation at the time of diluting the solution in water, removing the solvent with an evaporator or the like according to a conventional method under reduced pressure conditions, or by aeration.
- the device for applying an external shearing force include a turbine type agitator and a homogenizer.
- At least one of the block copolymers having the ability to form micelles and a drug in the solvent of the present invention and a drug are dissolved in a solvent, then placed in a dialysis tube and dialyzed in water, and the solvent is removed to form micelles.
- the solvent used here is not particularly limited as long as it can dissolve the block copolymer and is miscible with water.
- methanol, ethanol, dimethylacetamide, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, dioxane, acetone, and acetonitrile are used. Any of these can be used alone or in combination of two or more.
- the ratio of the block copolymer to the solvent is not particularly limited.
- the dialysis membrane the block copolymer used An appropriate molecular weight fraction size may be selected depending on the molecular weight, and a cellulose membrane is often used, but is not limited thereto.
- an additive may be added to the dialysis solution.
- additives include pH adjusting agents (eg, phosphate buffer, carbonate buffer, acetate buffer, dilute hydrochloric acid, sodium hydroxide, etc.), anionic surfactants, nonionic surfactants, polyoxy Ethylene castor oil derivatives, polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxymethyl cellulose, lecithin, gelatin, hyaluronic acid and other emulsifiers, and saccharides such as mannitol.
- the dialysis time is about 5 minutes to about 24 hours at a time, but the micelles are prepared by repeating the liquid exchange operation of the outer water phase one or more times.
- the preparation temperature is about 0 to about 80 ° C, more preferably about 5 ° C to about 5 Ot.
- the micelle prepared in this way can be obtained in a dialysis membrane from a transparent state to a slightly cloudy state.
- the form of the micelle that can be formed by the block copolymer having a hydrophobic Z hydrophilic segment can be changed by the preparation method.
- micelles are prepared in a large amount of aqueous solution after dissolving or dispersing the block copolymer in an organic solvent, it becomes an OZW type, with a hydrophobic segment as the inner core and a hydrophilic segment in the outer shell.
- the block copolymer is dissolved or dispersed in an aqueous solution and then micelles are prepared in a large amount of organic solvent, it becomes WZO type, with the hydrophilic segment as the inner core and the hydrophobic segment as the outer shell. It becomes a distributed form.
- core Z-shell micelles having a hydrophobic segment as an inner core and a hydrophilic segment as an outer shell.
- the hydrophobic segments of the block copolymer aggregate and aggregate at a high density to form a core, and the hydrophilic segments extend outward from the particle surface.
- the ends of the hydrophilic segment are protected or modified, the presence of partial aggregation of the hydrophilic segment is also considered.
- These preparation methods can also be changed according to the purpose. For example, when a drug is encapsulated, it is determined by physical properties such as solubility and stability of the drug in water or an organic solvent.
- the average particle size of the drug-containing micelles or aggregates obtained by the above method is preferably in the state dispersed in water, for example, I nm to: I, 100 nm, more preferably 5 nm to 50 0 nm, particularly preferably 5 nm to 3 0 0 n m.
- the determinants of these particle sizes are the composition of the block copolymer and its preparation method.
- the particle diameter can be changed according to the purpose of use, it is not limited to these particle diameters.
- the particle diameter can be measured by a known method. For example, a light scattering measurement method or a microscopic observation is used.
- freeze-drying or vacuum-drying can be performed in the state of being dispersed in water after the formation of drug-containing micelles and stored as a dry powder.
- Additives can also be added for the purpose of inhibiting aggregation during the drying operation.
- additives include mannitol, lactose, glucose, trehalose, starches, hyaluronic acid or alkali metal salts thereof, water-soluble polysaccharides, polyethylene glycol, glycine, fibrin, collagen and other proteins, sodium chloride sodium, Inorganic salts such as sodium hydrogen phosphate are used.
- the amount of the additive added is not particularly limited as long as aggregation suppression is achieved when the micelles are redispersed.
- the block copolymer of the present invention in which a ligand is bound to a hydrophilic segment has an ability to get in vivo.
- the polymer micelle according to the present invention can be prepared under relatively mild conditions, and is suitable for maintaining the activity of a ligand and encapsulating an unstable drug.
- the block copolymer of the present invention can be used for solubilization of a hydrophobic compound in water, as can be understood from the above performance.
- polymeric micelles are usually a preparation with a hydrophobic segment as the core, it is preferable that the drug to be encapsulated is hydrophobic, but in the case of a compound having a hydrophobic part even if it is water-soluble, its hydrophobicity It is also possible to form micelles with the present block copolymer in part.
- specific organs eg, kidney, liver, lung, knee, brain, etc.
- diseased part / organ eg, cancer, inflammatory part, etc.
- the block copolymer of the present invention can stably encapsulate these drugs in the inner core portion of a micelle composed of a hydrophobic segment.
- the method for encapsulating a drug of the present invention comprises a polymer -Add to the solution to allow preparation of polymeric micelles with the drug and hydrophobic segments as the core and hydrophilic segments on the surface.
- an appropriate solvent can be added to trap the drug efficiently.
- a solvent such as chloroform to stabilize the hydrophobic environment in the block copolymer and to encapsulate the drug.
- polymer micelles are prepared in advance using a block copolymer, and a drug dissolved in a solvent is added to the polymer micelle solution to allow the drug to penetrate into the core part of the polymer micelle.
- a polymer micelle is prepared in advance using a block copolymer, and the drug is added to the polymer micelle solution and kneaded to allow the drug to penetrate into the core part of the polymer micelle.
- the hydrophobic drug to be encapsulated include those described above.
- the core hydrophilic segments preferably also 1 polymeric micelle hydrophobic segment shea El, which hydrophilic drug encapsulated within the core of the polymeric micelles, sustained release And drug stability.
- the hydrophilic drug the same ones as described above are used.
- an underwater drying method for example, an underwater drying method, an ultrasonic treatment method, a freeze drying method, or the like is used, and these are used alone or in combination.
- At least one of the block copolymers having the ability to form fine particles and a drug in the solvent of the present invention and a drug are dissolved in a solvent, and then added to water little by little with stirring, and the solvent is removed or diffused in water. Prepare microparticles.
- the solvent used here is not particularly limited as long as it can dissolve the block polymer and the drug.
- methanol, ethanol, benzene, toluene, dimethylacetamide, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxane, acetone, acetonitrile, or a mixture of these with water is used. These can be used alone or in combination with two or more solvents.
- the amount of water can be arbitrarily selected.
- the preparation temperature is preferably about 0 to about 80 V, more preferably about 5 X: to about 50.
- Examples of the device for applying the external shearing force include a turbine type agitator and a homogenizer.
- block copolymers of the present invention at least one type of block copolymer capable of forming fine particles and a drug are dissolved in an appropriate solvent and dispersed in a large amount of water.
- an appropriate solvent for example, in the range of 1 W to about 200 W, preferably 1 W to about 10 W, 1 second to about 24 hours, more preferably 1 minute Perform ultrasonic irradiation for about 5 hours.
- the preparation temperature is in the range of about 0 ° C. to about 80 ° C., preferably about 5 to 50 °. Often done in combination with the above-mentioned underwater drying method.
- the content of the block copolymer in the fine particles of the present invention is usually from 10 to 100% by weight, preferably from 30 to 100% by weight, based on the whole fine particles.
- the content ratio of the drug in the microparticles of the present invention is determined by the therapeutically necessary amount> no particular limitation.
- the fine particles of the present invention include, for example, a dispersant (surfactant such as polysorbate 80, polyoxyethylene hydrogenated castor oil 60; polysaccharides such as carboxymethylcellulose, sodium alginate, sodium hyaluronate; Polyethylene glycol 400, etc.), preservatives (eg, methyl paraoxybenzoate, propyl parabenzoate), tonicity agents (eg, sodium chloride, mannitol, sorbitol, glucose), fats and oils (eg, sesame oil) , Corn oil, etc.), phospholipids (eg, lecithin, etc.), excipients (eg, lactose, corn starch, mannitol, cellulose, etc.), binders (eg, sucrose, gum arabic, methylcellulose, carboxymethylcellulose, dextrin) Etc.) It may be mixed with a disintegrating agent (for example, carboxymethylcellulose calcium, etc.).
- a dispersant surfactant
- a drug complex can be produced by adding a drug to an aqueous solution of the block copolymer and kneading. By kneading efficiently, a complex of nano-order drug crystals and the block copolymer can be formed, and the suspended state of the drug can be kept stable.
- the micelles, microparticles or complexes containing the drug of the present invention are formulated into various dosage forms by adding various pharmaceutical additives, and injected or implanted (for example, intravenous administration, subcutaneous administration, intramuscular administration, skin Intramucosal, indirect cavity administration, tissue administration, etc.), transmucosal agents (eg, oral mucosa, nasal, suppositories, vaginal, pulmonary, etc.), transdermal agents (eg, ointments) , Creams, gels, etc.), oral preparations (eg, tablets, capsules, granules, etc.).
- various pharmaceutical additives for example, intravenous administration, subcutaneous administration, intramuscular administration, skin Intramucosal, indirect cavity administration, tissue administration, etc.
- transmucosal agents eg, oral mucosa, nasal, suppositories, vaginal, pulmonary, etc.
- transdermal agents eg, ointments
- micelles or microparticles containing the drug of the present invention are used as surfactants (for example, polysorbate, polyoxyethylene hydrogenated castor oil), dispersants (for example, carboxymethylcellulose, sodium alginate).
- surfactants for example, polysorbate, polyoxyethylene hydrogenated castor oil
- dispersants for example, carboxymethylcellulose, sodium alginate
- Aqueous solutions and suspensions can also be made into lyophilized preparations by lyophilization.
- the micelles or microparticles containing the drug of the present invention can be used as a safe medicine for mammals.
- the dosage of micelles or microparticles containing the drug of the present invention varies depending on the type and content of the main drug, dosage form, administration route, target disease, target animal, etc., but it may be an effective drug amount.
- the administration frequency is 1 to several times a day. Once a week, once every two weeks, once a month, or once every few months, depending on the type and content of the main drug, dosage form, route of administration, target disease, target animal, etc. You can select as appropriate. '
- the block copolymer of the present invention can form a hydrophobic compound, micelles, fine particles, and composites.
- hydrophobic compounds can be solubilized and can be administered intravenously. Accumulation at the diseased site is also possible with a ligand.
- this block copolymer is biocompatible and can be expected to have sustained drug efficacy due to its sustained release. Improvement of oral absorbability can also be expected by micellization.
- microparticles can be expected to release drugs over a long period of time as subcutaneous injections, and composites can be made into nanoparticulates of poorly absorbable drugs and can be expected to improve oral absorption.
- the block copolymer of the present invention imparts various properties such as selectivity by changing the type and number of constituent amino acids, the type and number of hydroxycarboxylic acids, the sequence order, or the modifying group. Examples that can be-,
- Polyethylene glycol having an average molecular weight of 4,00 0 (HO—PEG 4 0 0 0 —OH) 2 0 0 g (0 0 5 mol) was dissolved in 40 0 mL of acetonitrile.
- the obtained didepsipeptide hydrochloride was dissolved in 40 OmL of THF, and 28 mL of pyridine was added with stirring. To this solution was added 121 g (0 37 mol) of Bo c—Leu-ON ! Su, and 5 mL of NMM (0 35 mol) was added with stirring. Stir overnight at room temperature. The solution was concentrated under reduced pressure, and the residue was dissolved in 50 OmL of ethyl acetate. This solution was treated as described above to give 1 15 g (88%) of Boc 1 Leu—A 1 a—Lac—OH.
- the tridepeptidic peptide Boc group was removed and reacted with Boc-Leu-ONSu to obtain 127 g (85%) of Boc-LeuLeuA1a-Lac-OH.
- This Boc-tetradepsipeptide was dissolved in 40 OmL of THF, and 34.5 g (0.3 mol) of N-hydroxysuccinimide (HOSu) was added. The solution was cooled to ⁇ 10, 55.4 g (0.27 mol) of dicyclohexyl carpositimide was added, and stirred at ⁇ 10 ° C. for 3 hours and at room temperature overnight.
- Bo c— Leu— Phe— ⁇ — PEG 4000 — OH 40 g (9.2 mmol) was treated with 4 M dioxane hydrochloride to remove the Boc protecting group.
- the obtained hydrochloride was dissolved in ACN-THF (1: 1), and 1 mL of NMM was added.
- t-butoxycarbolulu L-sucrose isil- L-sicyl-isyl-L-alanyl-l-L-lactic acid-N-hydroxysuccinimide ester (B oc-L eu-L eu- A 1 a — L ac— ONS u) 8 1 g (13.9 mmol) was added, and the mixture was stirred overnight at room temperature.
- Boc— (Leu-LeuA la-La c) 4 of Example 4 Le u— Phe — O— PEG ⁇ oo— OH
- B oc protecting group was removed by treatment with 4M-dioxane hydrochloride.
- Boc- (Leu-Leu-A la-Lac) 5 Leu— Phe is reacted with B o c-Leu-Le uA 1 a—L ac— ⁇ NS u in the same operation and conditions as in Example 1.
- — ⁇ — PEG 4000 — ⁇ H was obtained with a yield of 95%.
- Polyethylene glycol L monophenylalaninate hydrochloride synthesized in Reference Example 1 (38.9 g, 0.01 mol) is dissolved in 30 mL of acetonitrile (ACN) -tetrahydrofuran (THF) 1 ⁇ 1 mixed solvent, and NMM 1.
- ACN acetonitrile
- THF tetrahydrofuran
- NMM 1 acetonitrile
- Add 15 mL (0 0105 mol) and add 4.3 g (0 015 mol) of 1-butoxycarbonyl-L-lanalanin-N-hydroxysuccinimide ester (B oc-A 1 a- ONS u) In addition, the mixture was stirred overnight at room temperature.
- the obtained hydrochloride was dissolved in ACN-THF (1: 1) and 1 mL of NMM was added.
- NMM N-protected tetradepsipeptide active ester
- t-Butoxycarbolulu L—Mouth isyl-L—Mouth isyl-L-alanyl-L-glycolic acid mono-N-hydroxysuccinimide ester Bo c- Leu— Leu— A 1 a-He a-ONS ⁇
- Example 1 1 of Bo c- Leu- Le u-A l a-He aA 1 -P he -O _PEG 4. . .
- the OH Boc protecting group was removed by treatment with 4 M-dioxane hydrochloride, and B oc- Leu- Leu- Ala- He a- ON Su was reacted with this by the same procedure as above.
- — (L e uL e uA 1 a-He a) 2 -A 1 a — Ph e— ⁇ — PEG 4000 _ ⁇ H was obtained with a yield of 89%.
- Boc-Le Example 13 u- Leu- A l a-Lac- (Leu-Le u- A l a-He a) 2 -A 1 a-Ph e- ⁇ - PEG 4. . .
- Boc-Leu-Leu-A1a-Lac_ONSu is reacted in the same manner as above, , Boc— (Le u — Leu— A la— L ac) 2 — (L eu— L eu— A 1 a— Hea) 2 — A la — P he— O— PEG 4000 — OH is 92% Obtained at a rate.
- Example 15 Example 15
- the B oc protecting group of ⁇ H is removed by treatment with 4 M-Z dioxane, and B oc -L eL e uA 1 a—L ac— ON S u is reacted in the same manner as above.
- ACN acetonitrile
- THF tetrahydrofuran
- the solution was concentrated under reduced pressure, the residue was dissolved in dichloromethane, and the solution was washed with 10% aqueous sodium hydrogen carbonate solution, saturated aqueous citrate solution, and water, and dried over anhydrous sodium sulfate.
- the solution was concentrated under reduced pressure, and ether was added to the residue;
- Boc-Phe-Leu-Phe-Lac-Phe-O-PEG 400 was dissolved in THF and recrystallized with ether. Yield 45 4 g (9 6%).
- Boc-Phe-Leu-Phe-Lac-Phe—O_PEG 4000 —OH 47.3 g (10 mmol) was treated with 4 M hydrochloric acid / dioxane to remove the B oc protecting group.
- the obtained hydrochloride was dissolved in ACN—THF (1: 1), and 1.15 mL of NMM was added.
- the solution was concentrated under reduced pressure at 50, and 3 mL of water was added to the residue. The residue formed micelles and dissolved easily.
- this NMR spectrum forms micelles consisting of Bo c—P he—L ac— (Ph e-Le u-Ph eL ac) 2 —P he—O—PEG 40 oo—OH and DMP. .
- the solvent was distilled off under reduced pressure.
- To the residue add 50 mL of water and shake. After standing overnight, the resulting insoluble material was filtered through a 450 nm membrane fill. The weight of insoluble matter was 24 mg.
- the filtrate is divided into two, the one 25 Omg (Sample 1), and PEG 4 of 125 mg (sample 2) on the other. . 0 was added and freeze-dried.
- Boc— (Leu-Leu ⁇ Ala-La c) 5 Leu— P he— O— PEG 4000 -OH 100 mg and DMP 5 mg were prepared. Dialysis was performed using a dialysis cellulose tube having a pore diameter of about 5 nm and the released DMP was measured with an ultraviolet spectrophotometer. 2% was released after 24 hours and 4% was released after 48 hours.
- Boc— (Le u-Leu-A la— La c) 5 — Le u-Phe-O— PE G 4000 -OH l O Omg and DMP 10 mg were prepared, and this was used as a permeated molecular weight of about 14, 000, dialyzed and with pore size of about 5 nm cellulose tube for dialysis, and the released DMP was measured by ultraviolet spectrophotometer. 24% was released after 24 hours.
- Bo c- (Leu-Leu-A la-La c) 5 -L eu -P he -OP EG 4000 -OH A micelle solution consisting of 100 mg and dexamethasone 5 mg was prepared, and this was used as a permeated molecular weight of about 14,000. Dialysis was performed using a cellulose tube for dialysis having a pore diameter of about 5 nm, and the released DMP was measured with an ultraviolet spectrophotometer. 57% was released after 10 hours, and only 3% was released over the next 10 hours.
- the affinity between the drug and the block copolymer of the present invention varies greatly from drug to drug, and the polymer structure of the hydrophobic segment in the micelle is adjusted to match the chemical properties of the drug. It was found that micelle formation can be controlled by constructing for each drug. It was also found that the release of the drug encapsulated in the micelle can be controlled by the structure of the drug and the block copolymer of the present invention and the amount of drug encapsulated.
- dexamethasone palmitate 1 Omg Take dexamethasone palmitate 1 Omg in a mortar and mix it with Boc— (L eu— Leu— A la-L ac) 5 -A 1 a— Phe— ⁇ — PEG 4000 — OH 10 Omg in 15 mL of water.
- Boc— (L eu— Leu— A la-L ac) 5 -A 1 a— Phe— ⁇ — PEG 4000 — OH 10 Omg in 15 mL of water.
- dexamethasone palmitate crystals were uniformly dispersed in an extremely fine crystalline state, and this suspension was sufficiently stable at room temperature.
- add dexamethasone palmitate 1 Omg to an agate mortar, add ImL of water to it, and add agate milk.
- lipid microsphere injection solution of dexamethasone palmitate (Remethasone (registered trademark), manufactured by Mitsubishi Wellpharma Co., Ltd.), dexamethasone sodium phosphate injection solution (Decadron (registered trademark)) (Manufactured by Manyu Pharmaceutical Co., Ltd.)
- dexamethasone palmitate Remethasone (registered trademark)
- dexamethasone sodium phosphate injection solution Decadron (registered trademark)
- Manufactured by Manyu Pharmaceutical Co., Ltd. the same volume of drug-free physiological saline was administered, and the foot volume was measured with the same time schedule.
- drug-free saline the foot volume increased by 19.9 ⁇ 7.7%, and in Lime Yuzon, it increased by 15 4 3 5%.
- Bo c— (Leu— Leu— A la— La c) — Leu— Phe— O— PE G 4000 -OH 6 mg and prostaglandin I 2 (PG I 2 ) 0. 12 mg in 10 OmL eggplant-shaped flask 3 OmL of acetonitrile and THF-ethanol Dissolved in (5: 5: 1). The solvent was distilled off from this solution under reduced pressure. Distilled water (3 OmL) was added to the obtained film to dissolve the film in water. The film was completely dissolved in water. The UV spectrum was then measured. Even after 3 days, the UV spectrum with an absorption maximum at 19 ⁇ nm did not change. In addition, 3 mg of PEG400 was added to this aqueous solution and lyophilized. The UV spectrum did not change even after the lyophilized product was stored at room temperature for 24 days.
- Nocritaxel 2 mg and Boc— (Le u-Le u-Le ⁇ aL ac) 5 -L eu-Phe-O-PEG 4000 -OH 5 mg are dissolved in 10 mL of acetonitrile and the solvent is distilled off under reduced pressure. Left.
- the transparent film remaining on the glass wall was dissolved in 3 OmL of water at 40. Although paclitaxel is insoluble in water, the film was completely soluble in water, and no insoluble matter was deposited, suggesting that it was incorporated into micelles.
- the clear homogeneous solution was filtered through a membrane fill, and 25 mg of PEG4000 was added to the filtrate and lyophilized. Lyophilized samples were measured in D 2 0 and dimethyl sulfoxide 1 d 6 (DMS 0-d 6 ) by 50 OMhz proton NMR.
- the spectrum measured in the D 2 0 solvent is 3.8 p pm with a peak derived from the methylene proton of polyethylene oxide and 5.0 Only two types of proton peaks from water present in the system were observed at P pm.
- the spectrum in DMSO-d 6 of the same sample Bo c- (Le u- Le u- A la- La c) 5 L eu- P he- ⁇ one PEG 400. 1 All proton peaks from OH and paclitaxel were observed.
- this NMR spectrum shows that micelles consisting of B oc— (L e uL e uA 1 aL ac) 5 —L e li-P he—O—PEG 4000 — ⁇ H and paclitaxel are formed. It can be said that it shows.
- FCA Greenethyl omp leteadjuvant
- FIA FIA
- Sensitization was performed by administering FCA emulsion at the first dose and FIA emulsion at a dose of 2 SmlZkg subcutaneously in the back and foo tp ad in the second and third weeks.
- the induction reaction was Bo c- (Leu- Leu-Ala- Lac) 5 — Leu— Phe— O— PEG 4000 -OH (dose 4 OmgZk g) as the test substance, and ovalbumin 0. 4 mg / kg), saline was used as a negative control. These substances were adjusted with physiological saline so as to have predetermined concentrations.
- the dose was 1. OmlZkg, induced in the veins of the forelimbs or hind limbs and observed for 4 hours. Thereafter, the body weight was measured once a week for one month and the general condition was observed.
- the number of animals is Bo c— (L eu— L eu— A la— L ac) 5 — L eu— Ph e— O— PEG 4000 — OH group: 4 animals, ovalbumin group: 3 animals, physiological saline group: Three animals were used.
- Boc- (Leu-Leu-Ala-Lac) 5 —Leu—Phe—O—PEG 40 00 —OH showed no anaphylactic reaction. There was no particular abnormality in the general condition and body weight thereafter.
- anaphylactic symptoms were observed in all individuals immediately after challenge.
- Bo c— (Le u-Le uA la-Lac) 5 Le u— Ph e— ⁇ —PEG 40 .
- Active systemic anaphylaxis (ASA) reaction test using OH guinea pigs was negative and found to be non-antigenic
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0616877-9A BRPI0616877A2 (pt) | 2005-10-05 | 2006-10-02 | copolìmero em bloco biocompatìvel, micela, particulado, compósito, composição farmacêutica, método para fabricar uma micela, particulado ou compósito, e, uso de um copolìmero em bloco biocompatìvel |
US12/083,155 US20090258079A1 (en) | 2005-05-10 | 2006-10-02 | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof |
CA002624910A CA2624910A1 (en) | 2005-10-05 | 2006-10-02 | Biocompatible block copolymer, use thereof, and production method thereof |
EP06811467A EP1932870A1 (en) | 2005-10-05 | 2006-10-02 | Biocompatible block copolymer, use thereof, and production method thereof |
AU2006300451A AU2006300451A1 (en) | 2005-10-05 | 2006-10-02 | Biocompatible block copolymer, use thereof, and production method thereof |
JP2007515551A JP4259599B2 (ja) | 2005-10-05 | 2006-10-02 | 生体適合性ブロック共重合体、その用途および製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-292451 | 2005-10-05 | ||
JP2005292451 | 2005-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007043486A1 true WO2007043486A1 (ja) | 2007-04-19 |
Family
ID=37942728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/320140 WO2007043486A1 (ja) | 2005-05-10 | 2006-10-02 | 生体適合性ブロック共重合体、その用途および製造法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090258079A1 (ja) |
EP (1) | EP1932870A1 (ja) |
JP (1) | JP4259599B2 (ja) |
KR (1) | KR20080064827A (ja) |
CN (1) | CN101331173A (ja) |
AU (1) | AU2006300451A1 (ja) |
BR (1) | BRPI0616877A2 (ja) |
CA (1) | CA2624910A1 (ja) |
RU (1) | RU2008117425A (ja) |
WO (1) | WO2007043486A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102488A (ja) * | 2007-10-22 | 2009-05-14 | Gunma Univ | 温度応答性配列を含むデプシペプチド構造と親水性高分子構造からなるブロック共重合体 |
WO2009113645A1 (ja) * | 2008-03-10 | 2009-09-17 | 国立大学法人 東京大学 | 非荷電性親水性ブロック及び側鎖の一部に疎水性基が導入されカチオン性のポリアミノ酸ブロックを含んでなる共重合体、その使用 |
JP2010526183A (ja) * | 2007-04-30 | 2010-07-29 | インテザイン テクノロジーズ, インコーポレイテッド | 疎水性薬物のカプセル化のために混合立体化学を有するハイブリッドブロックコポリマー |
WO2011025036A1 (ja) * | 2009-08-31 | 2011-03-03 | ナノキャリア株式会社 | 粒子組成物及びこれを有する医薬組成物 |
WO2011099601A1 (ja) * | 2010-02-12 | 2011-08-18 | ナノキャリア株式会社 | 粒子状医薬組成物 |
JP2012509983A (ja) * | 2008-11-25 | 2012-04-26 | エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) | ブロックコポリマーおよびその使用 |
JPWO2012169518A1 (ja) * | 2011-06-07 | 2015-02-23 | ホソカワミクロン株式会社 | 液状組成物及びそれを用いた化粧料並びに育毛剤 |
CN104415011A (zh) * | 2013-08-30 | 2015-03-18 | 成都市绿科华通科技有限公司 | 细胞微环境pH敏感性胶束的制备方法 |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100987693B1 (ko) * | 2008-10-20 | 2010-10-13 | 서울대학교산학협력단 | 폴리(에틸렌 글리콜)-b-[폴리(L-세린)-g-폴리(D,L-락티드)]의 블록공중합체 및 이를 이용한 약물전달체용 나노입자의 제조 방법 |
EP2399885A1 (en) * | 2010-06-22 | 2011-12-28 | Ulrich Dietz | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification |
CN104856950A (zh) * | 2014-02-25 | 2015-08-26 | 苏州雷纳药物研发有限公司 | 一种紫杉醇胶束载药系统及其制备方法 |
KR101593313B1 (ko) * | 2014-07-15 | 2016-02-16 | 경북대학교 산학협력단 | Kb 암세포 센싱용 lc 마이크로액적 발광체, 이를 이용하여 kb 암세포를 센싱하는 방법 및 이를 이용한 바이오센서 |
CN108567971B (zh) * | 2018-06-13 | 2021-09-28 | 宁波三生生物科技股份有限公司 | 一种卡贝缩宫素注射液 |
CN110272539B (zh) * | 2019-07-04 | 2021-09-17 | 广东工业大学 | 一种用于结合pmsa的配体缀合物、探针及其制备方法和应用 |
CN110652595B (zh) * | 2019-10-21 | 2022-11-29 | 南通大学附属医院 | 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法 |
TWI760992B (zh) * | 2019-12-26 | 2022-04-11 | 財團法人工業技術研究院 | 接枝高分子與包含其之複合材料 |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06107565A (ja) | 1992-08-14 | 1994-04-19 | Res Dev Corp Of Japan | 物理吸着型高分子ミセル医薬 |
JPH06206832A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | 高分子担体 |
JPH06206830A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
JPH07188411A (ja) | 1987-12-23 | 1995-07-25 | Pfizer Inc | 生物吸収性デプシペプチド共重合体、その製造法および用途 |
JPH08188541A (ja) | 1995-01-10 | 1996-07-23 | Res Dev Corp Of Japan | 静電結合型高分子ミセル薬物担体とその薬剤 |
JPH1135679A (ja) | 1997-07-25 | 1999-02-09 | Dainippon Ink & Chem Inc | 生分解性ポリラクトンエステルアミド及びその製造法 |
JPH11100331A (ja) | 1997-09-26 | 1999-04-13 | Nano Career Kk | 薬物含有ポリマーミセルおよびその医薬製剤 |
JPH11269097A (ja) | 1998-01-20 | 1999-10-05 | Takeda Chem Ind Ltd | 新規な微粒子、その製造法および用途 |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
JP2001031762A (ja) | 1999-07-21 | 2001-02-06 | Sharp Corp | 乳酸系生分解性重合体 |
JP2001146556A (ja) | 1999-11-19 | 2001-05-29 | Nano Career Kk | コア−シェル構造のポリイオンコンプレックスミセル |
JP2001226294A (ja) | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
JP2001261838A (ja) * | 2000-02-14 | 2001-09-26 | Korea Advanced Inst Of Sci Technol | 医療用生分解性三元ブロック共重合体及びその製造方法 |
JP2001525357A (ja) | 1997-12-12 | 2001-12-11 | サミアン・コーポレーション | 遺伝子輸送のための生物分解性の混合重合体ミセル |
WO2002026241A1 (fr) | 2000-09-26 | 2002-04-04 | Center For Advanced Science And Technology Incubation, Ltd. | Micelle polymere renfermant du cisplatine et utilisation |
JP2002234934A (ja) | 2001-02-13 | 2002-08-23 | Japan Science & Technology Corp | 反応性置換基を有する生分解性重合体 |
WO2003000771A1 (fr) | 2001-06-20 | 2003-01-03 | Nippon Kayaku Kabushiki Kaisha | Copolymere bloc a taux d'impuretes reduit, support polymere, preparations pharmaceutiques sous forme polymere et procede de preparation associe |
JP2003012505A (ja) | 2001-07-06 | 2003-01-15 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥 |
JP2003026566A (ja) | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥用組成物およびその凍結乾燥製剤 |
JP2003026812A (ja) | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの製造方法 |
JP2003532688A (ja) | 2000-05-12 | 2003-11-05 | サムヤン コーポレイション | ブロック共重合体の相分離による高分子ミセルの製造方法 |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
JP2004269462A (ja) | 2003-03-11 | 2004-09-30 | Japan Science & Technology Agency | デプシペプチドの製造方法 |
JP2004352972A (ja) | 2003-05-08 | 2004-12-16 | Japan Science & Technology Agency | ポリエチレングリコール−ポリカチオンブロック共重合体 |
JP2005008614A (ja) | 2003-03-28 | 2005-01-13 | Nano Career Kk | 高分子ミセルを用いた眼科用ドラッグデリバリーシステム |
WO2005003214A1 (ja) | 2003-07-07 | 2005-01-13 | Nof Corporation | 三元ブロック共重合体、その製造法及び生体内適合材料 |
JP2005501831A (ja) | 2001-08-01 | 2005-01-20 | スミスクライン・ビーチャム・コーポレイション | プロドラッグおよび薬剤デリバリービヒクル |
JP2005029480A (ja) | 2003-07-08 | 2005-02-03 | Nano Career Kk | ピルビニウムを内包した高分子ミセルを含有する抗癌剤 |
JP2005336402A (ja) * | 2004-05-28 | 2005-12-08 | Kanagawa Acad Of Sci & Technol | 薬物送達用高分子ドラッグキャリヤーシステム |
WO2006033296A1 (ja) * | 2004-09-22 | 2006-03-30 | Nippon Kayaku Kabushiki Kaisha | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
WO2006090924A1 (ja) * | 2005-02-28 | 2006-08-31 | The University Of Tokyo | ペプチドリガンドを有するブロック共重合体 |
WO2006098496A1 (ja) * | 2005-03-18 | 2006-09-21 | The University Of Tokyo | ジアミノシクロヘキサン白金(ii)とブロック共重合体との配位化合物及びそれを含有する抗がん剤 |
-
2006
- 2006-10-02 RU RU2008117425/04A patent/RU2008117425A/ru not_active Application Discontinuation
- 2006-10-02 US US12/083,155 patent/US20090258079A1/en not_active Abandoned
- 2006-10-02 KR KR1020087008247A patent/KR20080064827A/ko not_active Application Discontinuation
- 2006-10-02 CN CNA2006800442636A patent/CN101331173A/zh active Pending
- 2006-10-02 BR BRPI0616877-9A patent/BRPI0616877A2/pt not_active IP Right Cessation
- 2006-10-02 WO PCT/JP2006/320140 patent/WO2007043486A1/ja active Application Filing
- 2006-10-02 CA CA002624910A patent/CA2624910A1/en not_active Abandoned
- 2006-10-02 EP EP06811467A patent/EP1932870A1/en not_active Withdrawn
- 2006-10-02 JP JP2007515551A patent/JP4259599B2/ja not_active Expired - Fee Related
- 2006-10-02 AU AU2006300451A patent/AU2006300451A1/en not_active Abandoned
Patent Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188411A (ja) | 1987-12-23 | 1995-07-25 | Pfizer Inc | 生物吸収性デプシペプチド共重合体、その製造法および用途 |
JPH06107565A (ja) | 1992-08-14 | 1994-04-19 | Res Dev Corp Of Japan | 物理吸着型高分子ミセル医薬 |
JPH06206832A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | 高分子担体 |
JPH06206830A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
JPH08188541A (ja) | 1995-01-10 | 1996-07-23 | Res Dev Corp Of Japan | 静電結合型高分子ミセル薬物担体とその薬剤 |
JPH1135679A (ja) | 1997-07-25 | 1999-02-09 | Dainippon Ink & Chem Inc | 生分解性ポリラクトンエステルアミド及びその製造法 |
JPH11100331A (ja) | 1997-09-26 | 1999-04-13 | Nano Career Kk | 薬物含有ポリマーミセルおよびその医薬製剤 |
JP2001525357A (ja) | 1997-12-12 | 2001-12-11 | サミアン・コーポレーション | 遺伝子輸送のための生物分解性の混合重合体ミセル |
JPH11269097A (ja) | 1998-01-20 | 1999-10-05 | Takeda Chem Ind Ltd | 新規な微粒子、その製造法および用途 |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
JP2001031762A (ja) | 1999-07-21 | 2001-02-06 | Sharp Corp | 乳酸系生分解性重合体 |
JP2001146556A (ja) | 1999-11-19 | 2001-05-29 | Nano Career Kk | コア−シェル構造のポリイオンコンプレックスミセル |
JP2001226294A (ja) | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
JP2001261838A (ja) * | 2000-02-14 | 2001-09-26 | Korea Advanced Inst Of Sci Technol | 医療用生分解性三元ブロック共重合体及びその製造方法 |
JP2003532688A (ja) | 2000-05-12 | 2003-11-05 | サムヤン コーポレイション | ブロック共重合体の相分離による高分子ミセルの製造方法 |
WO2002026241A1 (fr) | 2000-09-26 | 2002-04-04 | Center For Advanced Science And Technology Incubation, Ltd. | Micelle polymere renfermant du cisplatine et utilisation |
JP2002234934A (ja) | 2001-02-13 | 2002-08-23 | Japan Science & Technology Corp | 反応性置換基を有する生分解性重合体 |
WO2003000771A1 (fr) | 2001-06-20 | 2003-01-03 | Nippon Kayaku Kabushiki Kaisha | Copolymere bloc a taux d'impuretes reduit, support polymere, preparations pharmaceutiques sous forme polymere et procede de preparation associe |
JP2003012505A (ja) | 2001-07-06 | 2003-01-15 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥 |
JP2003026566A (ja) | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥用組成物およびその凍結乾燥製剤 |
JP2003026812A (ja) | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの製造方法 |
JP2005501831A (ja) | 2001-08-01 | 2005-01-20 | スミスクライン・ビーチャム・コーポレイション | プロドラッグおよび薬剤デリバリービヒクル |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
JP2004269462A (ja) | 2003-03-11 | 2004-09-30 | Japan Science & Technology Agency | デプシペプチドの製造方法 |
JP2005008614A (ja) | 2003-03-28 | 2005-01-13 | Nano Career Kk | 高分子ミセルを用いた眼科用ドラッグデリバリーシステム |
JP2004352972A (ja) | 2003-05-08 | 2004-12-16 | Japan Science & Technology Agency | ポリエチレングリコール−ポリカチオンブロック共重合体 |
WO2005003214A1 (ja) | 2003-07-07 | 2005-01-13 | Nof Corporation | 三元ブロック共重合体、その製造法及び生体内適合材料 |
JP2005029480A (ja) | 2003-07-08 | 2005-02-03 | Nano Career Kk | ピルビニウムを内包した高分子ミセルを含有する抗癌剤 |
JP2005336402A (ja) * | 2004-05-28 | 2005-12-08 | Kanagawa Acad Of Sci & Technol | 薬物送達用高分子ドラッグキャリヤーシステム |
WO2006033296A1 (ja) * | 2004-09-22 | 2006-03-30 | Nippon Kayaku Kabushiki Kaisha | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
WO2006090924A1 (ja) * | 2005-02-28 | 2006-08-31 | The University Of Tokyo | ペプチドリガンドを有するブロック共重合体 |
WO2006098496A1 (ja) * | 2005-03-18 | 2006-09-21 | The University Of Tokyo | ジアミノシクロヘキサン白金(ii)とブロック共重合体との配位化合物及びそれを含有する抗がん剤 |
Non-Patent Citations (4)
Title |
---|
M. ASANO ET AL., BIOMATERIALS, vol. 10, 1989, pages 569 |
M. ASANO ET AL., J. CONTROLLED RELEASE, vol. 9, 1989, pages 111 |
M. ASANO ET AL., MIKROMOL. CHEM., vol. 84, 1983, pages 1761 |
T. MASHIMO ET AL., KANTO MEDICAL SCIENCE, vol. 41, 1991, pages 311 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526183A (ja) * | 2007-04-30 | 2010-07-29 | インテザイン テクノロジーズ, インコーポレイテッド | 疎水性薬物のカプセル化のために混合立体化学を有するハイブリッドブロックコポリマー |
JP2009102488A (ja) * | 2007-10-22 | 2009-05-14 | Gunma Univ | 温度応答性配列を含むデプシペプチド構造と親水性高分子構造からなるブロック共重合体 |
US8431545B2 (en) | 2008-03-10 | 2013-04-30 | The University Of Tokyo | Copolymer including uncharged hydrophilic block and cationic polyamino acid block having hydrophobic group in part of side chains, and use thereof |
WO2009113645A1 (ja) * | 2008-03-10 | 2009-09-17 | 国立大学法人 東京大学 | 非荷電性親水性ブロック及び側鎖の一部に疎水性基が導入されカチオン性のポリアミノ酸ブロックを含んでなる共重合体、その使用 |
JP5467366B2 (ja) * | 2008-03-10 | 2014-04-09 | 国立大学法人 東京大学 | 非荷電性親水性ブロック及び側鎖の一部に疎水性基が導入されたカチオン性のポリアミノ酸ブロックを含んでなる共重合体、その使用 |
US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
JP2012509983A (ja) * | 2008-11-25 | 2012-04-26 | エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) | ブロックコポリマーおよびその使用 |
US10335499B2 (en) | 2008-11-25 | 2019-07-02 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
JP2018188642A (ja) * | 2008-11-25 | 2018-11-29 | エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) | ブロックコポリマーおよびその使用 |
CN102481255B (zh) * | 2009-08-31 | 2015-04-22 | 那野伽利阿株式会社 | 颗粒组合物和含有其的医药组合物 |
JP4912510B2 (ja) * | 2009-08-31 | 2012-04-11 | ナノキャリア株式会社 | 粒子組成物及びこれを有する医薬組成物 |
CN102481255A (zh) * | 2009-08-31 | 2012-05-30 | 那野伽利阿株式会社 | 颗粒组合物和含有其的医药组合物 |
US9415059B2 (en) | 2009-08-31 | 2016-08-16 | Nanocarrier Co., Ltd. | Particulate composition and pharmaceutical composition containing the same |
WO2011025036A1 (ja) * | 2009-08-31 | 2011-03-03 | ナノキャリア株式会社 | 粒子組成物及びこれを有する医薬組成物 |
CN102753151A (zh) * | 2010-02-12 | 2012-10-24 | 那野伽利阿株式会社 | 颗粒状医药组合物 |
EP2918267A1 (en) * | 2010-02-12 | 2015-09-16 | NanoCarrier Co., Ltd. | Particulate pharmaceutical composition |
US9198860B2 (en) | 2010-02-12 | 2015-12-01 | Nanocarrier Co., Ltd. | Particulate pharmaceutical composition |
WO2011099601A1 (ja) * | 2010-02-12 | 2011-08-18 | ナノキャリア株式会社 | 粒子状医薬組成物 |
US9795563B2 (en) | 2010-02-12 | 2017-10-24 | Nanocarrier Co., Ltd. | Particulate pharmaceutical composition |
EP2415463A1 (en) * | 2010-02-12 | 2012-02-08 | NanoCarrier Co., Ltd. | Particulate medicinal composition |
EP2415463A4 (en) * | 2010-02-12 | 2012-02-29 | Nanocarrier Co Ltd | MEDICAL PARTICLE COMPOSITION |
JPWO2012169518A1 (ja) * | 2011-06-07 | 2015-02-23 | ホソカワミクロン株式会社 | 液状組成物及びそれを用いた化粧料並びに育毛剤 |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
CN104415011A (zh) * | 2013-08-30 | 2015-03-18 | 成都市绿科华通科技有限公司 | 细胞微环境pH敏感性胶束的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0616877A2 (pt) | 2011-07-05 |
AU2006300451A1 (en) | 2007-04-19 |
RU2008117425A (ru) | 2009-11-10 |
US20090258079A1 (en) | 2009-10-15 |
KR20080064827A (ko) | 2008-07-09 |
CN101331173A (zh) | 2008-12-24 |
JPWO2007043486A1 (ja) | 2009-04-16 |
CA2624910A1 (en) | 2007-04-19 |
EP1932870A1 (en) | 2008-06-18 |
JP4259599B2 (ja) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4259599B2 (ja) | 生体適合性ブロック共重合体、その用途および製造法 | |
ES2433010T3 (es) | Composición líquida de colorímetro de bloque biodegradable para sistema de administración fármaco y proceso para la preparación de la misma | |
JP3955759B2 (ja) | 有機溶媒に溶解可能なポリ(アルキレンオキサイド)及びポリ(p−ジオキサノン)の生分解性ブロック共重合体及びこれを含有するドラッグデリバリー組成物 | |
ES2531679T3 (es) | Composiciones para la administración de liberación controlada de péptidos | |
US9517203B2 (en) | Polymer particle delivery compositions and methods of use | |
CN101035512B (zh) | 用于生物活性化合物可控制释放递送的药物组合物 | |
CA2649672C (en) | Delivery of ophthalmologic agents to the exterior or interior of the eye | |
ES2269694T3 (es) | Copolimero de bloque afifilo cargado negativamente como vehiculo para farmacos y complejo del mismo con farmaco cargado positivamente. | |
CN101415442B (zh) | 控释凝胶 | |
JPH11513985A (ja) | ポリ(エーテル−エステル)ブロックコポリマーを基剤とする感熱生分解性ポリマー | |
ES2287297T3 (es) | Copolimero de bloque anfifilo cargado positivamente como vehiculo para farmaco y complejo del mismo con farmaco cargado negativamente. | |
WO2007084460A2 (en) | Pharmaceutical compositions with enhanced stability | |
CN102231981A (zh) | 蛋白质或肽的缓释给药组合物 | |
CA2596011A1 (en) | Polymer particle delivery compositions and methods of use | |
US20150099808A1 (en) | Amphiphilic copolymers and compositions containing such polymers | |
KR20070122519A (ko) | Peg-폴리아세탈 이블록 및 삼블록 공중합체 및 약학조성물 | |
JP2004527585A (ja) | 脂質−ポリマー結合体 | |
EP0531091B1 (en) | Biodegradable copolyester of 4-hydroxy proline and pharmaceutical composition containing the same | |
US20110070320A1 (en) | Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration | |
JPH11269097A (ja) | 新規な微粒子、その製造法および用途 | |
US20200048377A1 (en) | Thermosensitive phosphazene-based polymer comrising sulfonated moiety, and preparation method and use thereof | |
WO2010143218A1 (en) | Polymeric conjugates of phospholipids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680044263.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007515551 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2624910 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006811467 Country of ref document: EP Ref document number: 1020087008247 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006300451 Country of ref document: AU Ref document number: 1741/CHENP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006300451 Country of ref document: AU Date of ref document: 20061002 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008117425 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12083155 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0616877 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080404 |